Miyake Keisuke, Ogawa Daisuke, Okada Masaki, Hatakeyama Tetsuhiro, Tamiya Takashi
Department of Neurological Surgery, Kagawa University Faculty of Medicine.
Neurol Med Chir (Tokyo). 2016 Jul 15;56(7):396-408. doi: 10.2176/nmc.ra.2015-0305. Epub 2016 May 31.
Non-invasive positron emission tomography (PET) enables the measurement of metabolic and molecular processes with high sensitivity. PET plays a significant role in the diagnosis, prognosis, and treatment of brain tumors and predominantly detects brain tumors by detecting their metabolic alterations, including energy metabolism, amino acids, nucleic acids, and hypoxia. Glucose metabolic tracers are related to tumor cell energy and exhibit good sensitivity but poor specificity for malignant tumors. Amino acid metabolic tracers provide a better delineation of tumors and cellular proliferation. Nucleic acid metabolic tracers have a high sensitivity for malignant tumors and cellular proliferation. Hypoxic metabolism tracers are useful for detecting resistance to radiotherapy and chemotherapy. Therefore, PET imaging techniques are useful for detecting biopsy-targeting points, deciding on tumor resection, radiotherapy planning, monitoring therapy, and distinguishing brain tumor recurrence or progression from post-radiotherapy effects. However, it is not possible to use only one PET tracer to make all clinical decisions because each tracer has both advantages and disadvantages. This study focuses on the different kinds of PET tracers and summarizes their recent applications in patients with gliomas. Combinational uses of PET tracers are expected to contribute to differential diagnosis, prognosis, treatment targeting, and monitoring therapy.
非侵入性正电子发射断层扫描(PET)能够高灵敏度地测量代谢和分子过程。PET在脑肿瘤的诊断、预后评估和治疗中发挥着重要作用,主要通过检测脑肿瘤的代谢改变来发现它们,这些代谢改变包括能量代谢、氨基酸、核酸和缺氧情况。葡萄糖代谢示踪剂与肿瘤细胞能量相关,对恶性肿瘤具有良好的敏感性,但特异性较差。氨基酸代谢示踪剂能更好地勾勒肿瘤及细胞增殖情况。核酸代谢示踪剂对恶性肿瘤和细胞增殖具有高敏感性。缺氧代谢示踪剂有助于检测对放疗和化疗的耐药性。因此,PET成像技术可用于检测活检靶点、决定肿瘤切除、放疗计划制定、治疗监测以及区分脑肿瘤复发或进展与放疗后效应。然而,仅使用一种PET示踪剂无法做出所有临床决策,因为每种示踪剂都有其优缺点。本研究聚焦于不同类型的PET示踪剂,并总结了它们在胶质瘤患者中的近期应用情况。PET示踪剂的联合使用有望有助于鉴别诊断、预后评估、治疗靶点确定及治疗监测。